-
More than half of patients A1C returned to normal Lilly GIP/GLP-1 subjector astrogen Phase 3 clinical results
Time of Update: 2021-01-16
Eli Lilly and Company today announced that its glucose-dependent insulin-promoting polypeptide (GIP) and glutatrogen-like peptide-1 (GLP-1) subject double agonist, Tirzepatide, have obtained positive top-line results in a Phase 3 clinical trial called SURFASS-1.
-
Novarca's $770 million acquisition of Cadent
Time of Update: 2021-01-16
, Cadent received approval from the U.S. Food and Drug Administration (FDA) to launch a Phase I clinical trial of Schizophrenia CAD-303.
, Novartic teamed up with Sangamo Therapeutics to develop gene-regulating therapies for three neurodevelopmental targets.
-
Potential "best-in-class"! The third generation APK inhibitor of Tagri Bio was approved clinically
Time of Update: 2021-01-16
On December 17th, according to the Drug Review Center (CDE) of the State Drug Administration of China, Tagri Bio obtained two clinical trials with TGRX-326 tablets submitted in category 1 of the chemical, with the proposed development of analyte as ALK-positive or/or ROS1-positive advanced non-small cell lung cancer (NSCLC).
-
Nidanib has been approved for new adaptations in China
Time of Update: 2021-01-16
, according to an earlier press release issued by Blinger Ingeham, the new adaptation approved is for the treatment of aggressive fibrosis interstitiotic lung disease (PF-ILD).
-
Treatment of ulcerative colitis AbbVie JAK inhibitors reaches phase 3 clinical end
Time of Update: 2021-01-16
AbbVie today announced that its JAK inhibitor, upadacitinib, has reached the primary endpoint of clinical remission and all critical secondary endpoints in Phase 3 clinical trials for adult patients treating moderate ulcerative colitis.
-
And platinum medicine is officially listed on the Hong Kong Stock Exchange today
Time of Update: 2021-01-16
According to the HKEx IPO announcement, and Platinum Pharmaceuticals was officially listed on the main board of the Hong Kong Stock Exchange on December 10. Pharmaceuticals filed an IPO application
-
The Koxing Bio23 price pneumonia vaccine has been approved for sale in China
Time of Update: 2021-01-16
the vaccine is intended for people 2 years and older with an increased risk of pneumococcal infection and is used to prevent infectious diseases caused by the 23 serotype pneumococcal species mentioned above.
-
The Pfizer pneumococcal vaccine is eligible for FDA priority review to protect 20 serotonypes
Time of Update: 2021-01-16
Pfizer (Pfizer) announced today that the U.S. FDA has accepted a biological product licensing application (BLA) for its 20-price pneumococcal coupled vaccine (20vPnC) to prevent invasive diseases and pneumonia caused by Streptococcus pneumoniae in adults over the age of 18.
-
Hengrui PD-L1 monoantigen initiated Phase III clinical target for small cell lung cancer
Time of Update: 2021-01-15
The clinical trial initiated by insight database () is a randomized, double-blind, controlled, multi-center Phase III clinical study designed to evaluate the safety and effectiveness of SHR-1316/placebo combined platinum chemotherapy (etoposide plus carpiate) for the treatment of small cell lung cancer.
-
What are the realities and dilemmas behind the departure of 18 pharmaceutical company chairman in 2020?
Time of Update: 2021-01-15
in February, Wang Qunbin, who had been with the company's founder Guo Guangchang for 28 years, was promoted to co-chairman and will no longer serve as CEO, while Chen Qiyu, the former co-president of the company, and Xu Xiaoliang were promoted to co-CEO.
-
Beda Pharmaceuticals intends to issue H shares and apply for listing on the main board of the Hong Kong Stock Exchange
Time of Update: 2021-01-15
On January 7, Beda Pharmaceuticals announced that its board of directors had considered and approved the company's issuance of foreign-listed foreign shares (H-shares) and applied for listing on the
-
Givetini tablets, a wholly owned subsidiary of Tiansli, obtained a drug registration certificate
Time of Update: 2021-01-15
On the evening of January 8th, Tiansli announced that its wholly-owned subsidiary, Jiangsu Tiansli Diyi Pharmaceutical Co., Ltd., had recently received a "drug registration certificate" approved and
-
Tiansli Bio suspended the listing of the board
Time of Update: 2021-01-15
announced that on August 31, 2020, Tianshili Biopharmaceutical Co., Ltd. submitted to the Shanghai Stock Exchange the Application Report of Tianshili Biopharmaceutical Co., Ltd. for the Initial Public Offering of Shares and listing on the Board of Science and Technology (Shanghai Division (2020) No. 01) and related application documents.
-
"IPO New Year" capital continues to contribute to innovative research and development 2020 Bio-industry listing summary
Time of Update: 2021-01-15
have all followed the domestic alternative route, and Peijia Medical's public offering has been oversubscribed nearly 1200 times, with a frozen capital of more than 260 billion yuan, earning the new stock "King of Gold Absorption"; medical devices start later than foreign enterprises, there is a certain market space for import substitution.
-
The first domestic research and development of a new generation of NTRK/ROS1 multi-kinase inhibitors project completed Phase I clinical
Time of Update: 2021-01-15
The first domestic research and development of a new generation of NTRK/ROS1 multi-kinase inhibitor SIM1803-1A tablets in China on January 5, 2021 completed the first phase I clinical trial subjects of the first drug.
-
The Pfizer/BioNTech vaccine is protective against the new coronavirus mutation
Time of Update: 2021-01-15
recently, researchers from Pfizer and the University of Texas Medical Branch released a new study on the preprinted site bioRxiv, showing that BNT62b2, a new crown vaccine developed jointly by Pfizer and BioNTech, still has the same protection against strains carrying the N501Y gene mutation.
-
Tiansli osteoporosis drug minoic acid tablets were approved for drug registration
Time of Update: 2021-01-15
On January 6, Tiansli announced that its wholly-owned subsidiary, Jiangsu Tiansli Diyi Pharmaceutical Co., Ltd., received a "drug registration approval" approved by the State Drug Administration for
-
Hainan Hai Medicine wrote off the private placement of Changsha Hai Pharmaceuticals and terminated its investment in the Apricot Zexingfu Fund
Time of Update: 2021-01-11
announcement shows that according to its focus on the development of the pharmaceutical industry business strategy needs, while in order to integrate and optimize the allocation of existing resources, improve the company's overall operating efficiency, reduce operating and management costs, the company has changsha hai medicine private placement liquidation and write-off.
-
Novartic BTK inhibitor "Abtini tablets" have been officially approved for the market
Time of Update: 2021-01-11
approved by NMPA on June 10 this year, the winning bid is 176.6 yuan / 80mg / grain, CLL / SLL adaptation treatment costs of 258,000 yuan.
-
Genesis Group announced the completion of a $105 million cross-round financing
Time of Update: 2021-01-11
On December 23rd The Group announced the successful completion of a $105 million cross-round financing.
January 2020, The Company announced the successful completion of a $100 million B-plus round of financing.
: The Company completed a $105 million cross-round financing.
